← FDA Drug Approvals (Drugs@FDA)
DOLUTEGRAVIR; TENOFOVIR DISOPROXIL FUMARATE; LAMIVUDINE
NDA · New Drug Application · Sponsor: STRIDES PHARMA · Approved 2023-09-14
Drug application
- FDA Application #
NDA217016- Application type
- New Drug Application
- Brand name
- DOLUTEGRAVIR; TENOFOVIR DISOPROXIL FUMARATE; LAMIVUDINE
- Generic name
- Dolutegravir
- Active ingredients
- DOLUTEGRAVIR; TENOFOVIR DISOPROXIL FUMARATE; LAMIVUDINE
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- None (Tentative Approval)
- Sponsor
- STRIDES PHARMA
- First approval
- 2023-09-14
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown